New study aims to help cancer survivors ditch opioids for good
NCT ID NCT06574009
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests four different approaches—behavioral therapy, physical therapy, medication changes, and buprenorphine rotation—to help cancer survivors reduce their opioid use while keeping pain under control. It involves 294 veterans who have finished cancer treatment but still struggle with chronic pain. The goal is to find which strategy works best to lower opioid doses without making pain worse.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Multimodal pain care (behavioral therapy, physical therapy, assistive devices, complementary therapies) and medication optimization (non-opioid drugs, buprenorphine rotation)
- What this could lead to
- If successful, this could provide a proven, safer way for cancer survivors to manage chronic pain without relying on opioids, reducing addiction and overdose risks.
- What could go wrong
- This is a Phase 4 trial, but it only includes veterans with certain cancers and no active disease, so results may not apply to all cancer survivors. The interventions may not work for everyone, and some may still need opioids.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
About 294 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2025
- Expected to finish
-
Dec 2029
An estimate. End dates often move.
- Lead sponsor
-
A government agency
The lead sponsor is a US federal agency other than the NIH.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 99 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Veterans must have had a qualifying solid tumor (bladder, breast, colorectal, head and neck, liver, lung, pancreas, prostate, or urinary tract) without evidence of active disease for at least 6 months * Participants must be 6 months away from their last receipt of cytotoxic, radiation, or surgical cancer treatments but can be on hormonal or biologic therapies needed to sustain remission or cancer control. * Participants must report pain \>=4 (on 0-10 NRS) on their last 3 recordings in the electronic medical record. Veterans should be on Long Term Opioid Therapy (LTOT) defined as: * a qualifying opioid analgesic dispensed within the prior 30 days * plus 150 days' supply of a qualifying opioid (fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone, oxymorphone) in the 180 days before the most recent dispensing date with no between-fill gaps \>40 days * There must be advance agreement from their existing opioid prescriber to resume opioid prescribing after study Exclusion Criteria: * Veterans with total daily opioid doses \>= 300 Morphine Milligram Equivalents (MME) will be excluded (higher doses require tapering prior to rotation to buprenorphine, which is something the investigators do not want to examine in this study) * Veterans with referrals or visits to a substance abuse clinic within the prior 2 years will be excluded to avoid including individuals requiring addiction expertise that is not available one the multidisciplinary pain teams * The investigators will also exclude Veterans with: * current or past use of buprenorphine * active alcohol use disorder or substance use * risk factors for opioid overdose (e.g. active suicidality or history of self-directed violence) * daily use of benzodiazepines * receipt of opioids from non-VA providers in the prior 3 months * or aberrant urine drug screen at baseline (cannabis is not exclusionary) * To ensure the relevance of our work to as many Veteran cancer survivors as possible, the investigators will not exclude subjects meeting DSM criteria for opioid use disorder if their only source of opioids is the VA
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cancer survivor are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Richard L. Roudebush VA Medical Center, Indianapolis, IN
NOT_YET_RECRUITINGIndianapolis, Indiana, 46202-2884, United States
-
VA Ann Arbor Healthcare System, Ann Arbor, MI
RECRUITINGAnn Arbor, Michigan, 48105, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- One 2-Hour class may help new mothers manage Post-Cesarean pain
- Zapping deep brain regions to quiet chronic back pain
- Can an experimental pill boost cancer immunotherapy? early trial puts HG146 to the test
- New injectable drug tested for safety in Hard-to-Treat solid tumors
- Herbal injections at acupuncture points tested against physical therapy for Long-Lasting sciatica
- Can exercise boost brain and body health during opioid treatment?